Heterogeneous nuclear ribonucleoprotein K is overexpressed and associated with poor prognosis in gastric cancer

Yang,Ruirui; Zeng,Ying; Xu,Haifan; Chen,Zhuo; Xiang,Mengqin; Fu,Yun; Yin,Yufang; Zhong,Jing; Zeng,Min; Wang,Peihua; You,Qin; Zeng,Xi

doi:10.3892/or.2016.4845

Heterogeneous nuclear ribonucleoprotein K is overexpressed and associated with poor prognosis in gastric cancer

Authors:
- Ruirui Yang
- Ying Zeng
- Haifan Xu
- Zhuo Chen
- Mengqin Xiang
- Yun Fu
- Yufang Yin
- Jing Zhong
- Min Zeng
- Peihua Wang
- Qin You
- Xi Zeng
View Affiliations

Affiliations: Key Laboratory of Tumor Cellular and Molecular Pathology of the College of Hunan Province, Cancer Research Institute, University of South China, Hengyang, Hunan 421001, P.R. China, School of Nursing, University of South China, Hengyang, Hunan 421001, P.R. China, The Department of Surgical Oncology, The First Affiliated Hospital, University of South China, Hengyang, Hunan 421001, P.R. China, Department of Pharmacology, Southern Illinois University School of Medicine, Springfield, IL 62702, USA, Institute of Clinical Medicine, The First Affiliated Hospital, University of South China, Hengyang, Hunan 421001, P.R. China
Published online on: June 2, 2016 https://doi.org/10.3892/or.2016.4845
Pages: 929-935

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is one of the major pre-mRNA-binding proteins, that is involved in translational modifications. In our previous studies, we found that hnRNP K is associated with human gastric cancer. The protein levels of hnRNP K were detected in cell lines and tissue microarrays. The correlation between hnRNP K expression and patient survival rate was evaluated by Kaplan-Meier survival analysis. In addition, we also detected hnRNP K expression in preoperative and postoperative serum samples from patients with gastric cancer, and serum samples from healthy volunteers. We found that hnRNP K was overexpressed in the gastric cancer cell lines. The levels of hnRNP K were significantly elevated in the gastric cancer tissues compared with that noted in the tumor-adjacent gastric mucosal and normal gastric mucosal sampes, and hnRNP K expression was found to correlate with tumor stage and lymph node metastasis. However, the level of serum hnRNP K did not differ significantly between gastric cancer patients and healthy volunteers. We also found that patients whose tumors showed elevated expression of hnRNP K had poor survival. The present study suggests that hnRNP K is a promising tissue biomarker for diagnosing gastric cancer and is a prognostic indicator for patients with gastric cancer.

View Figures

View References

1	Luyimbazi D, Nelson RA, Choi AH, Li L, Chao J, Sun V, Hamner JB and Kim J: Estimates of conditional survival in gastric cancer reveal a reduction of racial disparities with long-term follow-up. J Gastrointest Surg. 19:251–257. 2015. View Article : Google Scholar
2	Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, Forman D and Bray F: Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012. Eur J Cancer. 49:1374–1403. 2013. View Article : Google Scholar : PubMed/NCBI
3	Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F, Negri E, La Vecchia C and Lunet N: Worldwide trends in gastric cancer mortality (1980–2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 50:1330–1344. 2014. View Article : Google Scholar : PubMed/NCBI
4	Deng X, Jin X, Xue S, Zhang X, Su H, Zhang P and Xie C: Postoperative chemoradiotherapy for advanced gastric cancer after D2 gastrectomy. Hepatogastroenterology. 61:1472–1477. 2014.PubMed/NCBI
5	Zheng CH, Lu J, Huang CM, Li P, Xie JW, Wang JB and Lin JX: Treatment of locally advanced gastric cancer with the XELOX program of neoadjuvantchemotherapy combined with laparoscopic surgery: The experience in China. Hepatogastroenterology. 61:1876–1882. 2014.
6	Jiang X, Du L, Wang L, Li J, Liu Y, Zheng G, Qu A, Zhang X, Pan H, Yang Y, et al: Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. Int J Cancer. 136:854–862. 2015. View Article : Google Scholar
7	Zeng X, Liao AJ, Tang HL, Yi L, Xie N and Su Q: Screening human gastric carcinoma-associated antigens by serologic proteome analysis. Ai Zheng. 26:1080–1084. 2007.In Chinese. PubMed/NCBI
8	Wang F, Zhang P, Shi C, Yang Y and Qin H: Immunohistochemical detection of HSP27 and hnRNP K as prognostic and predictive biomarkers for colorectal cancer. Med Oncol. 29:1780–1788. 2012. View Article : Google Scholar
9	Chen Y, Li W and Zhang S: hnRNP K expression and its clinical significance in human lung cancer tissues. Zhongguo Fei Ai Za Zhi. 11:241–245. 2008.In Chinese. PubMed/NCBI
10	Guo Y, Zhao J, Bi J, Wu Q, Wang X and Lai Q: Heterogeneous nuclear ribonucleoprotein K (hnRNP K) is a tissue biomarker for detection of early hepatocellular carcinoma in patients with cirrhosis. J Hematol Oncol. 5:372012. View Article : Google Scholar : PubMed/NCBI
11	Namikawa T, Kobayashi M and Hanazaki K: Esophageal tumor after radical surgery for gastric cancer. Gastroenterology. 148:e9–e10. 2015. View Article : Google Scholar : PubMed/NCBI
12	Don KR, Ramani P, Ramshankar V, Sherlin HJ, Premkumar P and Natesan A: Promoter hypermethylation patterns of P16, DAPK and MGMT in oral squamous cell carcinoma: A systematic review and meta-analysis. Indian J Dent Res. 25:797–805. 2014. View Article : Google Scholar
13	Gross H, Hennard C, Masouris I, Cassel C, Barth S, Stober-Grässer U, Mamiani A, Moritz B, Ostareck D, Ostareck-Lederer A, et al: Binding of the heterogeneous ribonucleoprotein K (hnRNP K) to the Epstein-Barr virus nuclear antigen 2 (EBNA2) enhances viral LMP2A expression. PLoS One. 7:e421062012. View Article : Google Scholar : PubMed/NCBI
14	Barboro P, Salvi S, Rubagotti A, Boccardo S, Spina B, Truini M, Carmignani G, Introini C, Ferrari N, Boccardo F, et al: Prostate cancer: Prognostic significance of the association of heterogeneous nuclear ribonucleoprotein K and androgen receptor expression. Int J Oncol. 44:1589–1598. 2014.PubMed/NCBI
15	Zhao Y, Jin X, Tian T and Yu DH: Expression of hnRNPK in gastric carcinoma and its relationship with Helicobacter pylori L-form infection. Zhonghua Zhong Liu Za Zhi. 33:759–763. 2011.In Chinese.
16	Xia YJ, Ma YY, He XJ, Wang HJ, Ye ZY and Tao HQ: Suppression of selenium-binding protein 1 in gastric cancer is associated with poor survival. Hum Pathol. 42:1620–1628. 2011. View Article : Google Scholar : PubMed/NCBI
17	Xiang M, Zeng Y, Yang R, Xu H, Chen Z, Zhong J, Xie H, Xu Y and Zeng X: u6 is not a suitable endogenous control for the quantification of circulating microRNAs. Biochem Biophys Res Commun. 454:210–214. 2014. View Article : Google Scholar : PubMed/NCBI
18	Thompson PJ, Dulberg V, Moon KM, Foster LJ, Chen C, Karimi MM and Lorincz MC: hnRNP K coordinates transcriptional silencing by SETDB1 in embryonic stem cells. PLoS genet. 11:e10049332015. View Article : Google Scholar : PubMed/NCBI
19	Wojtuszkiewicz A, Assaraf YG, Maas MJ, Kaspers GJ, Jansen G and Cloos J: Pre-mRNA splicing in cancer: The relevance in oncogenesis, treatment and drug resistance. Expert Opin Drug Metab Toxicol. 11:673–689. 2015. View Article : Google Scholar
20	Boisvert M, Bouchard-Lévesque V, Fernandes S and Tijssen P: Classic nuclear localization signals and a novel nuclear localization motif are required for nuclear transport of porcine parvovirus capsid proteins. J Virol. 88:11748–11759. 2014. View Article : Google Scholar : PubMed/NCBI
21	Cao W, Razanau A, Feng D, Lobo VG and Xie J: Control of alternative splicing by Forskolin through hnRNP K during neuronal differentiation. Nucleic Acids Res. 40:8059–8071. 2012. View Article : Google Scholar : PubMed/NCBI
22	Adolph D, Flach N, Mueller K, Ostareck DH and Ostareck-Lederer A: Deciphering the cross talk between hnRNP K and c-Src: The c-Src activation domain in hnRNP K is distinct from a second interaction site. Mol Cell Biol. 27:1758–1770. 2007. View Article : Google Scholar :
23	Moritz B, Lilie H, Naarmann-de Vries IS, Urlaub H, Wahle E, Ostareck-Lederer A and Ostareck DH: Biophysical and biochemical analysis of hnRNP K: Arginine methylation, reversible aggregation and combinatorial binding to nucleic acids. Biol Chem. 395:837–853. 2014. View Article : Google Scholar : PubMed/NCBI
24	Osborne MJ and Borden KL: The eukaryotic translation initiation factor eIF4E in the nucleus: Taking the road less traveled. Immunol Rev. 263:210–223. 2015. View Article : Google Scholar
25	Wen F, Shen A, Shanas R, Bhattacharyya A, Lian F, Hostetter G and Shi J: Higher expression of the heterogeneous nuclear ribonucleoprotein k in melanoma. Ann Surg Oncol. 17:2619–2627. 2010. View Article : Google Scholar : PubMed/NCBI
26	Belli AK, Elibol F and Ozcan O: Other factors related to the completion of treatment after breast cancer. Breast. 24:2832015. View Article : Google Scholar : PubMed/NCBI
27	Xiao Z, Ko HL, Goh EH, Wang B and Ren EC: hnRNP K suppresses apoptosis independent of p53 status by maintaining high levels of endogenous caspase inhibitors. Carcinogenesis. 34:1458–1467. 2013. View Article : Google Scholar : PubMed/NCBI
28	Ling H, Fabbri M and Calin GA: MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov. 12:847–865. 2013. View Article : Google Scholar : PubMed/NCBI
29	Carpenter B, McKay M, Dundas SR, Lawrie LC, Telfer C and Murray GI: Heterogeneous nuclear ribonucleoprotein K is over expressed, aberrantly localised and is associated with poor prognosis in colorectal cancer. Br J Cancer. 95:921–927. 2006. View Article : Google Scholar : PubMed/NCBI
30	Wu CS, Chang KP, Chen LC, Chen CC, Liang Y, Hseuh C and Chang YS: Heterogeneous ribonucleoprotein K and thymidine phosphorylase are independent prognostic and therapeutic markers for oral squamous cell carcinoma. Oral Oncol. 48:516–522. 2012. View Article : Google Scholar : PubMed/NCBI
31	Inoue A, Sawata SY, Taira K and Wadhwa R: Loss-of-function screening by randomized intracellular antibodies: identification of hnRNP-K as a potential target for metastasis. Proc Natl Acad Sci USA. 104:8983–8988. 2007. View Article : Google Scholar : PubMed/NCBI